CDNA CareDx, Inc.
8-K Current Report
Filed: February 25, 2026
Health Care
Services-Medical LaboratoriesCareDx, Inc. (CDNA) 8-K current report filed with SEC EDGAR on February 25, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items3 items
- Item 5.02: Departure/Election of Directors or Officers
- Item 7.01: Regulation FD Disclosure
- Item 2.02: Results of Operations and Financial Condition
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Q4 2025 earnings released Feb 24, 2026 — full results in Exhibit 99.1
- • Quarter ended Dec 31, 2025 covered; specific financials available in attached press release
Item 5.02 · Departure/Election of Directors or Officers
- • Keith Kennedy (age 56) elevated from COO to CFO+COO dual role, effective Feb 26, 2026 — adds financial oversight to existing operational responsibilities
- • Kennedy brings prior CFO experience at Veracyte and PharmaLogic; CFA + CPA credentials signal strong financial controls background
Item 7.01 · Regulation FD Disclosure
- • Updated corporate presentation posted to website, current as of Feb 24, 2026
- • Reg FD disclosure ensures institutional and retail investors receive simultaneous access to material information
Other CareDx, Inc. 8-K Filings
Get deeper insights on CareDx, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.